Electromed heads into the back half of its fiscal year with momentum on two fronts: a clean earnings beat and a fresh analyst target raise arriving in the same 24-hour window.
The company reported Q3 2026 results on May 12, posting EPS of $0.35 against a $0.24 consensus estimate — a 46% beat — while revenue of $18.6 million cleared the $17.5 million estimate by roughly 6%. Management flagged that Smart Order adoption has reached 40% of orders, and the company outlined plans to add four to five sales reps next year. The stock responded: it rose 4.9% on the day and is up 5.4% on the week, extending a one-month gain of 12.8% to close at $27.20.
The analyst reaction has been quick. B. Riley Securities raised its price target to $40 from $38 on May 13, maintaining its Buy rating — the most current move from a covered firm. That follows a pattern of steadily rising targets across the coverage group, with Freedom Broker having lifted to $36 in February and Roth Capital sitting at $36 after a raise last November. The mean target of $37.33 sits 37% above the current price, an unusually wide gap that reflects genuine Street conviction rather than stale optimism: every tracked action over the past year has been a raise, no downgrades or cuts. Bulls point to homecare revenue growth of nearly 15%, distributor sales up 41%, and hospital sales up 52% as evidence the growth engine is broadening. Bears counter that margin compression and rising SG&A — up 17% — are a structural drag that could crimp profitability as the company scales its sales force.
Short positioning tells a quiet story. Short interest is just 2.1% of the free float — low enough to be a non-factor in either direction. It spiked sharply to around 10.9% week-on-week mid-period, but nearly half that build reversed in a single session on May 12, falling 8.4% in one day to 171,759 shares. Borrowing costs have been easing since April, dropping 63% over the past month to a negligible 0.58% annually. Availability in the lending market is very loose. There is no meaningful squeeze dynamic in play, and no bearish crowding to speak of.
Options activity adds a small note of caution. The put/call ratio has climbed to 0.086, about 1.5 standard deviations above its 20-day average of 0.060. That is still a historically low ratio — call volume dominates heavily — but the relative move suggests a modest uptick in hedging demand this week. Worth noting the 52-week high on the PCR is 0.97, so current levels are nowhere near defensive territory; the signal is more a marginal shift than an alarm.
Institutional ownership is broadly stable. Vanguard and BlackRock each hold just over 5.4% of shares and both added small positions in the most recent quarter. Hunter Associates added 30,250 shares as of March 31 — the most active incremental buyer in the holder list. The top two holders (Stephen Craney and George Winn, each over 6%) have not changed their registered positions recently, providing a steady anchor to the float.
What to watch next: the August 25 Q4 earnings print will be the first test of whether the planned sales-force expansion translates into revenue acceleration — and whether management can hold margins even as SG&A continues to grow.
See the live data behind this article on ORTEX.
Open ELMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
